Post-approval studies (Phase 4)UnknownNCT03468972What this trial is testingEffect of Immunosuppression in IgA NephropathyWho this might be right forBiopsy-proven IgA Nephropathy Yonsei University 174
Post-approval studies (Phase 4)Looking for participantsNCT06676384What this trial is testingWhich of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?Who this might be right forIgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more Christian Medical College, Vellore, India 585
Very early researchEnrolling By InvitationNCT07750249What this trial is testingThe MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.Who this might be right forPrimary IgA Nephropathy University Hospital, Martin 120